• Alias: BAY 57-9352
    • The orally bioavailable mesylate salt of the 17-AAG small-molecule inhibitor of several receptor protein tyrosine kinases
    • Binds to and inhibits VEGFR-1 and -2, PDGFR-β, and KIT, which may result in the inhibition of angiogenesis and cellular proliferation in tumors in which these receptors are upregulated
    • Currently no open clinical trials open in the United States
    • Half-life: 5 to 10 hours
    • Recommended phase 2 dose: 900 mg twice daily
    • Common side effects: Hypertension, diarrhea, anorexia, fatigue
    (Eskens et al., 2009; Strumberg et al., 2008)
    Other topics in Targeted and Immunotherapy Agents